BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32869445)

  • 1. A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1.
    Xu D; Zhao L; Jiang J; Li S; Sun Z; Huang X; Li C; Wang T; Sun L; Li X; Jiang Z; Zhang L
    J Cachexia Sarcopenia Muscle; 2020 Oct; 11(5):1306-1320. PubMed ID: 32869445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway.
    Xu DQ; Zhao L; Li SJ; Huang XF; Li CJ; Sun LX; Li XH; Zhang LY; Jiang ZZ
    Acta Pharmacol Sin; 2021 Jul; 42(7):1080-1089. PubMed ID: 32939036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAK1 inhibition improves myoblast differentiation and alleviates fibrosis in a mouse model of Duchenne muscular dystrophy.
    Xu D; Li S; Wang L; Jiang J; Zhao L; Huang X; Sun Z; Li C; Sun L; Li X; Jiang Z; Zhang L
    J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):192-208. PubMed ID: 33236534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pannexin 1 dysregulation in Duchenne muscular dystrophy and its exacerbation of dystrophic features in mdx mice.
    Freeman E; Langlois S; Leyba MF; Ammar T; Léger Z; McMillan HJ; Renaud JM; Jasmin BJ; Cowan KN
    Skelet Muscle; 2024 Apr; 14(1):8. PubMed ID: 38671506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p-TAK1 acts as a switch between myoblast proliferation phase and differentiation phase in mdx mice via regulating HO-1 expression.
    Fan S; Huang X; Tong H; Hong H; Lai Z; Hu W; Liu X; Zhang L; Jiang Z; Yu Q
    Eur J Pharmacol; 2022 Oct; 933():175277. PubMed ID: 36113553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.
    Whitehead NP; Kim MJ; Bible KL; Adams ME; Froehner SC
    Proc Natl Acad Sci U S A; 2015 Oct; 112(41):12864-9. PubMed ID: 26417069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
    Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
    J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
    Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
    Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy.
    Abou-Samra M; Selvais CM; Boursereau R; Lecompte S; Noel L; Brichard SM
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):518-533. PubMed ID: 31965757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
    Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
    Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striated muscle activator of Rho signalling (STARS) overexpression in the mdx mouse enhances muscle functional capacity and regulates the actin cytoskeleton and oxidative phosphorylation pathways.
    Sadler KJ; Gatta PAD; Naim T; Wallace MA; Lee A; Zaw T; Lindsay A; Chung RS; Bello L; Pegoraro E; Lamon S; Lynch GS; Russell AP
    Exp Physiol; 2021 Jul; 106(7):1597-1611. PubMed ID: 33963617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipin1 plays complementary roles in myofibre stability and regeneration in dystrophic muscles.
    Jama A; Alshudukhi AA; Burke S; Dong L; Kamau JK; Voss AA; Ren H
    J Physiol; 2023 Mar; 601(5):961-978. PubMed ID: 36715084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
    Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
    Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RhoA/ROCK2 signalling is enhanced by PDGF-AA in fibro-adipogenic progenitor cells: implications for Duchenne muscular dystrophy.
    Fernández-Simón E; Suárez-Calvet X; Carrasco-Rozas A; Piñol-Jurado P; López-Fernández S; Pons G; Bech Serra JJ; de la Torre C; de Luna N; Gallardo E; Díaz-Manera J
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1373-1384. PubMed ID: 35132805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy.
    Mucha O; Podkalicka P; Kaziród K; Samborowska E; Dulak J; Łoboda A
    Skelet Muscle; 2021 Sep; 11(1):21. PubMed ID: 34479633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heme Oxygenase-1 Influences Satellite Cells and Progression of Duchenne Muscular Dystrophy in Mice.
    Pietraszek-Gremplewicz K; Kozakowska M; Bronisz-Budzynska I; Ciesla M; Mucha O; Podkalicka P; Madej M; Glowniak U; Szade K; Stepniewski J; Jez M; Andrysiak K; Bukowska-Strakova K; Kaminska A; Kostera-Pruszczyk A; Jozkowicz A; Loboda A; Dulak J
    Antioxid Redox Signal; 2018 Jul; 29(2):128-148. PubMed ID: 29669436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.